Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-017422-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The main objective is to compare the activity of both the combination Temozolomide (TMZ) plus bevacizumab and TMZ alone in recurrent grade II or grade III glioma patients without 1p/19q co-deletion.


Critère d'inclusion

  • Recurrent grade II and grade III gliomas